This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
Stocks · News reference
8-K filing — Seaport Therapeutics, Inc. (SPTX)
Filed: 2026-08-03 AccNo: 0001193125-26-329528 Size: 335 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46
Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey secondary endpoint also